ADHD, Neurodivergence, and Lower Metabolic Baseline as ME/CFS Predisposition
1 Zametkin et al. 1990 — Cerebral Glucose Metabolism in ADHD Adults
Full Citation:: Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. New England Journal of Medicine. 1990;323(20):1361–1366. (Zametkin et al. 1990) DOI:: 10.1056/NEJM199011153232001 PMID:: 2233902 Article Type:: Original research (PET imaging) Key Findings::
- PET [18F]FDG: global cerebral glucose metabolism 8.1% lower in ADHD adults (n=25) vs controls (n=50)
- Largest reductions in premotor cortex and superior prefrontal cortex
- Significant hypometabolism in 30 of 60 brain regions examinedConclusion:: ADHD adults show widespread cerebral glucose hypometabolism. Foundational evidence for ADHD as a brain energy/metabolic deficit disorder. Limitations:: Adults only; task-state PET; pre-modern diagnostic criteria; no female-matched controls. ME/CFS Relevance:: Pre-existing prefrontal hypometabolism lowers the metabolic reserve threshold above which infection-triggered neuroinflammation produces sustained ME/CFS phenotype. Certainty Assessment::
- *Quality:* High (NEJM landmark)
- *Sample:* n=75
- *Replication:* Extensively replicated over 30 years
- *Score:* 0.802 Quadt et al. 2024 — Neurodivergent Traits, IL-6, and Chronic Disabling Fatigue (ALSPAC)
Full Citation:: Quadt L, Csecs J, Bond R, et al. Childhood neurodivergent traits, inflammation and chronic disabling fatigue in adolescence: a longitudinal case–control study. BMJ Open. 2024;14(7):e084203. (Quadt et al. 2024) DOI:: 10.1136/bmjopen-2024-084203 PMID:: 39038862 Article Type:: Longitudinal cohort study Key Findings::
- ALSPAC cohort (n=4,563): ADHD traits age 9 → OR=2.18 for chronic disabling fatigue at age 18
- Autism traits age 7 → OR=1.78 for chronic disabling fatigue at age 18
- IL-6 at age 9 mediated the pathway, independent of depressionConclusion:: Strongest prospective evidence that neurodivergent traits predict adolescent fatigue, with IL-6-mediated inflammation as mechanism. Limitations:: Screening instruments (not clinical diagnoses); CDF outcome not equivalent to ME/CFS criteria; IL-6 single timepoint. ME/CFS Relevance:: Establishes temporal precedence: neurodivergent traits → elevated IL-6 → chronic fatigue. Pre-existing neuroinflammation reduces metabolic reserve before any acute trigger. Certainty Assessment::
- *Quality:* High (large longitudinal cohort; mediation analysis)
- *Sample:* n=4,563
- *Replication:* Extends Norris 2017 in same cohort
- *Score:* 0.753 Sáez-Francàs et al. 2012 — ADHD Prevalence in Adult CFS Patients
Full Citation:: Sáez-Francàs N, Alegre J, Calvo N, et al. Attention-deficit hyperactivity disorder in chronic fatigue syndrome patients. Psychiatry Research. 2012;200(2–3):748–753. (Sáez-Francàs et al. 2012) DOI:: 10.1016/j.psychres.2012.04.041 PMID:: 22648008 Article Type:: Cross-sectional study Key Findings::
- 29.7% of 158 adult CFS patients had childhood ADHD; 20.9% had persistent adult ADHD
- CFS + ADHD patients: earlier CFS onset, more anxiety/depression, higher suicide risk
- ADHD severity and depressive symptoms independently predicted fatigue intensityConclusion:: ADHD is a common comorbidity in CFS (~30% childhood prevalence). Comorbid ADHD worsens prognosis. Limitations:: Cross-sectional; recall bias; single specialist clinic; Oxford CFS criteria. ME/CFS Relevance:: Primary source for ~30% childhood ADHD prevalence in CFS. Consistent with lower metabolic baseline predisposing to ME/CFS. Certainty Assessment::
- *Quality:* Medium (single-centre)
- *Sample:* n=158
- *Replication:* Partially replicated
- *Score:* 0.554 Yokokura et al. 2021 — D1R Reduction and Microglial Activation Co-Imaged in ADHD
Full Citation:: Yokokura M, Takedera K, Kazumata K, et al. In vivo imaging of dopamine D1 receptor and activated microglia in ADHD: a PET study. Molecular Psychiatry. 2021;26(9):4958–4967. (Yokokura et al. 2021) DOI:: 10.1038/s41380-020-0784-1 PMID:: 32439845 Article Type:: Original research (dual-tracer PET) Key Findings::
- Decreased D1R in anterior cingulate cortex; correlated with hyperactivity severity
- Increased activated microglia in DLPFC and orbitofrontal cortex
- D1R reduction and microglial activation positively correlated in ADHD onlyConclusion:: First in vivo co-imaging of dopaminergic deficit and neuroinflammation in ADHD subjects. Bridges the ME/CFS–ADHD pathway through both catecholamine depletion and microglial activation. Limitations:: n=24 per group; cross-sectional; causality indeterminate. ME/CFS Relevance:: ADHD brains show simultaneous catecholamine deficit and neuroinflammation — the same combination documented in ME/CFS. Certainty Assessment::
- *Quality:* High (dual-tracer PET; drug-naive)
- *Sample:* n=48
- *Replication:* Single study
- *Score:* 0.625 Moffitt et al. 2015 — Adult ADHD as Potentially Distinct from Childhood ADHD (Dunedin)
Full Citation:: Moffitt TE, Houts R, Asherson P, et al. Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. American Journal of Psychiatry. 2015;172(10):967–977. (Moffitt et al. 2015) DOI:: 10.1176/appi.ajp.2015.14101266 PMID:: 25998281 Article Type:: Longitudinal cohort study (Dunedin, 40 years) Key Findings::
- 90% of adult ADHD cases had no childhood ADHD diagnosis
- Only 5% of childhood ADHD persisted to adult criteria at age 38
- Adult-onset group: no neuropsychological deficits, no polygenic risk for childhood ADHDConclusion:: Challenges purely developmental framing of adult ADHD. Some adult ADHD may represent acquired catecholaminergic dysfunction. Limitations:: Single NZ birth cohort; adult ADHD assessed once at age 38; findings contested. ME/CFS Relevance:: If some adult-onset ADHD is biologically distinct (vs. adolescent-onset or missed childhood ADHD — see Sibley et al. 2018, Asherson and Agnew-Blais 2019, and Breda et al. 2020 below), a subset may represent acquired energy deficit — compatible with post-infectious ME/CFS trajectory, though the current consensus narrows this to a minority of cases. Certainty Assessment::
- *Quality:* High (gold-standard longitudinal cohort; 95% retention)
- *Sample:* n=1,037
- *Replication:* Contested
- *Score:* 0.706 Sibley et al. 2018 — Late-Onset ADHD Reconsidered (MTA)
Full Citation:: Sibley MH, Rohde LA, Swanson JM, et al. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. American Journal of Psychiatry. 2018;175(2):140–149. (Sibley et al. 2018) DOI:: 10.1176/appi.ajp.2017.17030298 PMID:: 29050505 Article Type:: Longitudinal follow-up (MTA comparison group, n=239) Key Findings::
- ~95% of individuals who screened positive on symptom checklists were excluded from a late-onset ADHD diagnosis on comprehensive assessment
- Most common exclusion: symptoms occurring exclusively in the context of heavy substance use
- Most late-onset cases were adolescence-limited; no evidence for adult-onset ADHD independent of a complex psychiatric historyConclusion:: Strongly qualifies the Moffitt 2015 distinct-syndrome reading: much apparent adult-onset ADHD reflects measurement artifact, comorbidity, or substance use. Limitations:: Single US cohort (MTA comparison group); ADHD assessment every ~2 years. ME/CFS Relevance:: If most adult-onset ADHD is adolescent-onset or missed-childhood rather than a distinct adult-onset syndrome, the “ADHD as acquired post-infectious catecholamine depletion” reading applies to a narrower subset. Certainty Assessment::
- *Quality:* High (repeated comprehensive multi-informant assessments)
- *Sample:* n=239
- *Replication:* Supports missed-childhood/artifact view
- *Score:* 0.657 Asherson and Agnew-Blais 2019 — Does Late-Onset ADHD Exist? (Annual Research Review)
Full Citation:: Asherson P, Agnew-Blais J. Annual research review: Does late-onset attention-deficit/hyperactivity disorder exist? Journal of Child Psychology and Psychiatry. 2019;60(4):333–352. (Asherson and Agnew-Blais 2019) DOI:: 10.1111/jcpp.13020 PMID:: 30843223 Article Type:: Annual Research Review (narrative synthesis) Key Findings::
- A significant proportion of young adults meeting ADHD criteria did not meet full criteria as children
- BUT most late-onset cases develop the disorder between ages 12--16 (adolescent-onset), many with childhood symptoms or an externalizing disorder (e.g., ODD)
- Impairing ADHD can emerge after 12 "although perhaps rarely in the context of a complete absence of precursors"
- Insufficient data to clarify whether early and late onset share the same neural mechanismsConclusion:: Provides the balanced current position between the distinct-syndrome reading (Moffitt 2015) and the missed-childhood/artifact view. Limitations:: Narrative review; limited data spanning young to older adulthood. ME/CFS Relevance:: The adolescent-onset profile (not de novo adult-onset) narrows the acquired-catecholamine interpretation of ADHD relevant to the ADHD–ME/CFS metabolic-reserve hypothesis. Certainty Assessment::
- *Quality:* High (authoritative review; Agnew-Blais, key figure in the debate)
- *Sample:* Review
- *Replication:* Aligns with Sibley 2018
- *Score:* 0.628 Breda et al. 2020 — ADHD Age-of-Onset Recall Reliability (Pelotas)
Full Citation:: Breda V, Rohde LA, Menezes AMB, et al. Revisiting ADHD age-of-onset in adults: to what extent should we rely on the recall of childhood symptoms? Psychological Medicine. 2020;50(5):857–866. (Breda et al. 2020) DOI:: 10.1017/S003329171900076X PMID:: 30968792 Article Type:: Prospective cohort (1993 Pelotas Birth Cohort, n=3,810 at age 22) Key Findings::
- Retrospective recall of childhood ADHD symptoms had accuracy of only 55.4%, sensitivity 32.8%, positive predictive value 40.7%
- Compared against childhood assessments at age 11Conclusion:: Retrospective recall is unreliable for establishing ADHD neurodevelopmental trajectory; much apparent adult onset may reflect missed or misrecalled childhood symptoms. Limitations:: Single Brazilian birth cohort; recall assessed at a single adult timepoint. ME/CFS Relevance:: Reinforces the caveat around Moffitt 2015: reported “adult-onset” ADHD may be forgotten childhood onset, so ADHD–ME/CFS comorbidity should not be assumed to reflect a genuinely distinct adult-onset syndrome. Certainty Assessment::
- *Quality:* High (prospective cohort, recall vs prospective comparison)
- *Sample:* n=3,810
- *Replication:* Consistent with recall-validity literature
- *Score:* 0.589 Gürbüzer et al. 2026 — SIRT-1/Nrf-2/HO-1 Axis in Adult ADHD
Full Citation:: Gürbüzer N, Ozkaya A, Mercantepe F. The SIRT-1/Nrf-2/HO-1 antioxidant defense axis in adult attention-deficit/hyperactivity disorder. Metabolic Brain Disease. 2026;41(1):85. (Gürbüzer, Ozkaya, and Mercantepe 2026) DOI:: 10.1007/s11011-026-01845-5 PMID:: 42012587 Article Type:: Cross-sectional case-control (60 adult ADHD vs 60 controls) Key Findings::
- Serum Nrf2, HO-1, and SIRT-1 significantly lower in ADHD than controls (all p < 0.001)
- Each negatively correlated with symptom severity; ROC AUC 0.756 (Nrf-2), 0.797 (HO-1)
- TNF-alpha did not differ between groupsConclusion:: First direct measurement of Nrf2 and its downstream effector HO-1 in ADHD patient blood; consistent with, but not proof of, a reduced antioxidant-defense state in adult ADHD. Limitations:: Measures circulating serum protein, not Nrf2 nuclear translocation or NQO1 target-gene expression; adult ADHD only; single study, unreplicated. ME/CFS Relevance:: Provides the first direct human evidence that the dopamine-NRF2-NLRP3 axis hypothesis’s premise (reduced NRF2 in ADHD) is measurable, giving the ADHD–ME/CFS shared-pathophysiology framework a concrete biomarker target. Certainty Assessment::
- *Quality:* Medium (cross-sectional; no replication)
- *Sample:* n=60 per group
- *Replication:* None
- *Score:* 0.5010 Frye et al. 2024 — ASD Mitochondrial Biomarkers Meta-Analysis (204 Studies)
Full Citation:: Frye RE, Rincon N, McCarty PJ, et al. Biomarkers of mitochondrial dysfunction in autism spectrum disorder: A systematic review and meta-analysis. Neurobiology of Disease. 2024;197:106520. (Frye et al. 2024) DOI:: 10.1016/j.nbd.2024.106520 PMID:: 38703861 Article Type:: Systematic review and meta-analysis Key Findings::
- 204 studies: elevated lactate (17%), pyruvate (41%), alanine (15%), creatine kinase (9%) in ASD
- Significant ATP deficit; moderate-to-large effect sizes (d ≥ 0.6)
- Mitochondrial dysfunction correlated with GI symptoms, oxidative stress, immune dysfunctionConclusion:: ASD involves systemic mitochondrial dysfunction. The same ETC impairments in ME/CFS energy failure are chronically active in ASD as a baseline feature. Limitations:: High heterogeneity; non-standardized assays; cause vs. consequence unclear. ME/CFS Relevance:: Core evidence that ASD reduces metabolic reserve via the same mitochondrial pathways as ME/CFS — a pre-existing lower baseline. Certainty Assessment::
- *Quality:* High (largest meta-analysis on this topic)
- *Sample:* 204 studies
- *Replication:* Consistent direction
- *Score:* 0.7011 Lai et al. 2019 — ADHD Prevalence in Autism: Meta-Analysis
Full Citation:: Lai M-C, Kassee C, Besney J, et al. Prevalence of co-occurring mental health diagnoses in the autism population: A systematic review and meta-analysis. The Lancet Psychiatry. 2019;6(10):819–829. (Lai et al. 2019) DOI:: 10.1016/S2215-0366(19)30289-5 Article Type:: Systematic review and meta-analysis Key Findings::
- Pooled ADHD prevalence 28% (95% CI 25--32) in ASD population — highest of all co-occurring conditions
- Anxiety disorders 20%, depressive disorders 11%, OCD 9%
- Clinical samples yielded higher estimates than population/registry-based studiesConclusion:: ADHD is the single most common co-occurring psychiatric condition in ASD. The prevalence far exceeds general-population base rates, confirming a genuine overlap not attributable to diagnostic inflation. Limitations:: High unexplained heterogeneity (all I2 > 95%); English/French-language only. ME/CFS Relevance:: Establishes the ADHD–ASD co-occurrence prevalence baseline that informs Architecture C’s compound-risk model. If 28% of autistic individuals also carry ADHD, both conditions’ independent metabolic reserve drains compound. Certainty Assessment::
- *Quality:* High (systematic meta-analysis in top journal)
- *Sample:* 96 studies
- *Replication:* Consistent direction
- *Score:* 0.9012 Ghirardi et al. 2018 — Familial Co-Aggregation of ASD and ADHD
Full Citation:: Ghirardi L, Brikell I, Kuja-Halkola R, et al. The familial co-aggregation of ASD and ADHD: A register-based cohort study. Molecular Psychiatry. 2018;23(2):257–263. (Ghirardi et al. 2018) DOI:: 10.1038/mp.2017.17 Article Type:: Register-based cohort study Key Findings::
- N=1,899,654 Swedish births (1987--2006); OR=22.33 (95% CI 21.77--22.92) for diagnosed ASD→ ADHD co-occurrence
- MZ twin OR=17.77 vs DZ twin OR=4.33 vs full sibling OR=4.59
- Stronger association for high-functioning ASD than low-functioning (with intellectual disability)Conclusion:: ADHD–ASD co-occurrence is not a clinical artifact — the pattern across decreasing genetic relatedness confirms substantial shared genetic liability. Limitations:: Swedish register data may not generalize globally; clinical diagnoses not standardized across all settings. ME/CFS Relevance:: If ADHD and ASD co-occur 22× more often than expected by chance, ME/CFS patients carrying one neurodevelopmental condition have dramatically elevated probability of carrying both — relevant to the multiplicative reserve reduction model. Certainty Assessment::
- *Quality:* High (largest familial co-aggregation study; top journal)
- *Sample:* ~1.9M individuals
- *Replication:* Consistent with twin literature
- *Score:* 0.9213 Ghirardi et al. 2019 — Genetic Overlap of ADHD and ASD Trait Dimensions in Adults
Full Citation:: Ghirardi L, Pettersson E, Taylor MJ, et al. Genetic and environmental contributions to the overlap between ADHD and ASD trait dimensions in young adults: A twin study. Psychological Medicine. 2019;49(14):2366–2373. (Ghirardi et al. 2019) DOI:: 10.1017/S003329171800243X Article Type:: Twin study Key Findings::
- N=6,866 young adults (20--28 yrs) from Swedish Twin Registry
- Inattention similarly correlated with restricted/repetitive behaviors (r=0.33) and social-communication difficulties (r=0.32)
- Hyperactivity/impulsivity more strongly linked to RRB (r=0.38) than SIC (r=0.24)
- Highest genetic correlation: HI--RRB (r~g~=0.56)Conclusion:: The ADHD–ASD genetic overlap is not uniform — specific symptom dimensions show different aetiological overlap strengths. Hyperactivity and repetitive behaviors share the strongest genetic signal. Limitations:: Self-report trait measures; cross-sectional; mainly European ancestry. ME/CFS Relevance:: Supports a dimensional, not categorical, model of neurodevelopmental risk — patients may carry subthreshold traits from both conditions that still drain metabolic reserve. Certainty Assessment::
- *Quality:* High (large adult twin study)
- *Sample:* n=6,866
- *Replication:* Consistent with childhood twin studies
- *Score:* 0.8514 Polderman et al. 2014 — Autistic and ADHD Dimensions in 17,770 Adult Twins
Full Citation:: Polderman TJC, Hoekstra RA, Posthuma D, Larsson H. The co-occurrence of autistic and ADHD dimensions in adults: An etiological study in 17,770 twins. Translational Psychiatry. 2014;4:e435. (Polderman et al. 2014) DOI:: 10.1038/tp.2014.84 Article Type:: Twin study Key Findings::
- N=17,770 adult twins; phenotypic correlation autistic-ADHD traits r=0.51
- Genetic correlation r~g~=0.54--0.60; no sex differences in etiology
- ADHD traits more heritable in adults than in childhoodConclusion:: The genetic overlap between ADHD and ASD traits persists into adulthood and is among the strongest genetic correlations in psychiatry. The dimensional continuum means subthreshold traits from both conditions can accumulate. Limitations:: Trait-based not clinical diagnosis; self-report; mainly European. ME/CFS Relevance:: The dimensional model (traits not just diagnoses) is key: a patient with mild ADHD traits plus mild ASD traits has additive metabolic reserve depletion even without formal dual diagnosis. Certainty Assessment::
- *Quality:* High (very large twin study)
- *Sample:* n=17,770
- *Replication:* Multiple twin studies converge
- *Score:* 0.8715 Ronald et al. 2008 — Overlapping Genetic Influences on Autistic and ADHD Behaviours
Full Citation:: Ronald A, Simonoff E, Kuntsi J, Asherson P, Plomin R. Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. Journal of Child Psychology and Psychiatry. 2008;49(5):535–542. (Ronald et al. 2008) DOI:: 10.1111/j.1469-7610.2007.01757.x Article Type:: Twin study Key Findings::
- N=6,768 twin pairs (TEDS), ages 7--9
- Correlation autistic-ADHD behaviours r=0.50--0.60
- Cross-twin cross-trait correlations: MZ > DZ → genetic overlap confirmedConclusion:: Strong genetic overlap between autistic traits and ADHD behaviours is present from childhood — not an artefact of adult recall or diagnostic drift. Limitations:: Community sample not clinical diagnosis; parent-report only; cross-sectional. ME/CFS Relevance:: Establishes that the ADHD–ASD shared diathesis is a lifespan feature, present before any ME/CFS trigger. This is central to Architecture C (pre-existing vulnerability). Certainty Assessment::
- *Quality:* High (large twin study, early demonstration of overlap)
- *Sample:* n=6,768 twin pairs
- *Replication:* Replicated in larger adult samples
- *Score:* 0.8316 Demontis et al. 2023 — Largest ADHD GWAS: 27 Risk Loci
Full Citation:: Demontis D, Walters GB, Athanasiadis G, et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics. 2023;55(2):198–208. (Demontis et al. 2023) DOI:: 10.1038/s41588-022-01285-8 Article Type:: GWAS Key Findings::
- Largest ADHD GWAS (N=38,691 cases, 186,843 controls)
- 27 genome-wide significant loci (up from 12 in prior GWAS)
- Genetic correlation ADHD--ASD: r~g~=0.36 (SE=0.06)
- Implicated cognitive domains and brain-expressed genesConclusion:: Substantially expanded ADHD genetic architecture with confirmed genetic overlap with ASD at the molecular level. Limitations:: European ancestry only; case-control design. ME/CFS Relevance:: Molecular confirmation that ADHD and ASD share common-variant genetic risk — these shared variants may also influence the immune and metabolic pathways that determine ME/CFS susceptibility. Certainty Assessment::
- *Quality:* High (largest ADHD GWAS; Nature Genetics)
- *Sample:* N=225,534
- *Replication:* Consistent with prior GWAS
- *Score:* 0.9318 Cross-Disorder Group PGC 2013 — Genetic Architecture Across Five Psychiatric Disorders
Full Citation:: Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics. 2013;45(9):984–994. (Cross-Disorder Group of the Psychiatric Genomics Consortium 2013) DOI:: 10.1038/ng.2711 Article Type:: Cross-disorder GWAS Key Findings::
- N=33,332 cases + 27,888 controls across 5 disorders (ASD, ADHD, BIP, MDD, SCZ)
- SNP-based genetic correlation ASD--ADHD: r~g~=0.32--0.38
- Two latent factors: psychotic (SCZ, BIP, MDD) and neurodevelopmental (ASD, ADHD)Conclusion:: ASD and ADHD genetically cluster together as neurodevelopmental disorders, distinct from the psychotic/mood cluster — the genetic architecture validates clinical comorbidity observations. Limitations:: Only common SNPs; ASD/ADHD samples smaller than SCZ; European ancestry. ME/CFS Relevance:: The neurodevelopmental genetic factor (shared by ADHD and ASD) may be a latent variable that independently reduces metabolic reserve. This is the genetic foundation for Architecture C. Certainty Assessment::
- *Quality:* High (landmark cross-disorder GWAS; Nature Genetics)
- *Sample:* N=61,220
- *Replication:* Consistent with later, larger GWAS
- *Score:* 0.8819 Taylor et al. 2019 — Psychiatric PRS and Dimensional Traits in Swedish Twins
Full Citation:: Taylor MJ, Martin J, Lu Y, et al. Association of genetic risk factors for psychiatric disorders and traits in a Swedish national twin sample. JAMA Psychiatry. 2019;76(3):280–289. (Taylor et al. 2019) DOI:: 10.1001/jamapsychiatry.2018.3652 Article Type:: Twin study with PRS analysis Key Findings::
- N=13,923 twin pairs at age 9
- ASD PRS → ASD traits ($\beta=0.04$, $p<0.01$); ADHD PRS → ADHD traits ($\beta=0.27$, $p<0.001$)
- Genetic factors for categorical diagnoses also influence continuous traits in the general populationConclusion:: The dimensional model of psychopathology is genetically validated — the same variants causing clinical disorders produce subthreshold traits in the broader population. Limitations:: Population-based — limited severe case representation; PRS predictive power modest. ME/CFS Relevance:: Key for the metabolic reserve model: even individuals with subthreshold ADHD/ASD traits (no formal diagnosis) carry genetic loading that may lower metabolic reserve. The categorical diagnosis is the visible tip of a genetic iceberg. Certainty Assessment::
- *Quality:* High (large twin study + PRS; JAMA Psychiatry)
- *Sample:* n=13,923 twin pairs
- *Replication:* Consistent with dimensional model literature
- *Score:* 0.8620 Hindley et al. 2022 — Charting Genetic Overlap Between Mental Disorders
Full Citation:: Hindley G, Frei O, Shadrin AA, et al. Charting the landscape of genetic overlap between mental disorders and phenotypes using large-scale genomic data. The American Journal of Psychiatry. 2022;179(11):833–842. (Hindley et al. 2022) DOI:: 10.1176/appi.ajp.21101051 Article Type:: MiXeR genomic analysis Key Findings::
- MiXeR analysis across 8 mental disorders (N up to 500K)
- ADHD and ASD extensively polygenic (~10K variants each)
- Highly overlapping variant sets across neurodevelopmental disorders
- ADHD shared more variants with ASD than with mood disordersConclusion:: The genetic overlap between neurodevelopmental disorders is more extensive than genetic correlation estimates alone suggest — variant-level overlap exceeds what rg captures. Limitations:: Cannot distinguish causal from tagging variants; European ancestry. ME/CFS Relevance:: The extensive variant overlap means ADHD and ASD do not just share broad genetic factors — they share thousands of specific variants. These variants likely influence the same metabolic and immune pathways relevant to ME/CFS. Certainty Assessment::
- *Quality:* High (state-of-the-art MiXeR analysis; top journal)
- *Sample:* up to N=500K
- *Replication:* First large-scale MiXeR for psychiatric disorders
- *Score:* 0.8721 Martin et al. 2014 — CNV Overlap Between ADHD and ASD
Full Citation:: Martin J, Cooper M, Hamshere ML, et al. Biological overlap of attention-deficit/hyperactivity disorder and autism spectrum disorder: Evidence from copy number variants. Journal of the American Academy of Child and Adolescent Psychiatry. 2014;53(7):761–770. (Martin et al. 2014) DOI:: 10.1016/j.jaac.2014.03.004 Article Type:: CNV burden analysis Key Findings::
- ADHD cases had increased CNV burden specifically at ASD-implicated loci
- Shared rare variant risk across neurodevelopmental pathways (synaptic, neuronal)
- Confirms shared biology beyond common variantsConclusion:: Rare CNVs contribute ADHD risk at the same genomic loci as ASD — the shared biology spans both common and rare variant architectures. Limitations:: CNV detection resolution limits; moderate sample size; cannot detect common variants. ME/CFS Relevance:: Neurodevelopmental pathway disruption (synaptic, neuronal genes) may have pleiotropic effects on the immune and metabolic systems relevant to ME/CFS susceptibility. Certainty Assessment::
- *Quality:* High (first demonstration of shared CNV burden)
- *Sample:* Moderate (not a mega-study)
- *Replication:* Consistent with GWAS overlap findings
- *Score:* 0.8222 Tesfaye et al. 2024 — Anxiety GWAS with ADHD/ASD Genetic Overlap
Full Citation:: Tesfaye M, Werme J, Frei O, et al. Novel genomic loci for anxiety and extensive genetic overlap with psychiatric disorders. Psychiatry and Clinical Neurosciences. 2024;78(12):700–708. (Tesfaye et al. 2024) DOI:: 10.1111/pcn.13742 Article Type:: GWAS Key Findings::
- N=301,732 anxiety GWAS (UKB + MVP)
- Anxiety polygenic with ~12.9K variants
- Shared loci: 20 with ADHD, 5 with ASD
- Cell adhesion and neurofibrillary pathways enrichedConclusion:: Anxiety shares extensive polygenic overlap with ADHD and ASD — anxiety may be a genetic bridge linking neurodevelopmental disorders to internalising symptoms (including fatigue). Limitations:: Anxiety self-report measure; limited non-European replication. ME/CFS Relevance:: Anxiety is highly prevalent in ME/CFS and independently linked to fatigue. The shared genetic architecture between anxiety and ADHD/ASD suggests a tripartite risk: ADHD/ASD genetic loading → elevated anxiety → further metabolic and HPA-axis drain. This adds a third pathway to the BH4 and IL-6 mediators already in the paper. Certainty Assessment::
- *Quality:* High (very large GWAS)
- *Sample:* N=301,732
- *Replication:* Consistent with prior anxiety GWAS
- *Score:* 0.8823 Baeza-Velasco et al. 2025 — Autism–Hypermobility–EDS Meta-Analysis
Full Citation:: Baeza-Velasco C, Vergne J, Poli M, et al. Autism in the context of joint hypermobility, HSD, and EDS: A systematic review and prevalence meta-analyses. Autism. 2025;29(8):1939–1958. (Baeza-Velasco et al. 2025) DOI:: 10.1177/13623613251328059 PMID:: 40145613 Article Type:: Systematic review and meta-analysis Key Findings::
- Joint hypermobility in autistic individuals: 22.3% (clinical: 31%)
- HSD/EDS in autistic samples: 27.9% (clinical: 39%)
- Autistic individuals 7.4× more likely to have EDS than comparison groupsConclusion:: Meta-analytically confirms ASD–EDS cluster. Since EDS → POTS → cerebral hypoperfusion, ASD + EDS = compounded lower baseline via mitochondrial dysfunction + cerebral hypoperfusion. Limitations:: Variable assessment methods; possible ascertainment bias. ME/CFS Relevance:: Highest-risk phenotype for ME/CFS: ASD + EDS combines two independent mechanisms of metabolic reserve reduction. Certainty Assessment::
- *Quality:* High (systematic meta-analysis)
- *Sample:* 20 studies; 12/15 significant
- *Replication:* Consistent
- *Score:* 0.7024 Csecs et al. 2022 — Joint Hypermobility Mediates Neurodivergence–Dysautonomia Link
Full Citation:: Csecs JLL, Iodice V, Rae CL, et al. Joint Hypermobility Links Neurodivergence to Dysautonomia and Pain. Frontiers in Psychiatry. 2022;12:786916. (Csecs et al. 2022) DOI:: 10.3389/fpsyt.2021.786916 PMID:: 35185636 Article Type:: Prospective cross-sectional with mediation analysis Key Findings::
- n=109 neurodivergent adults: 51% joint hypermobility (vs. 20% general population)
- Hypermobility statistically mediated neurodivergence → dysautonomia and pain
- Female prevalence: 69%Conclusion:: Connective tissue laxity is a mechanistic bridge linking neurodivergence to autonomic dysfunction and pain — the triad that characterises ME/CFS-adjacent presentations. Limitations:: Cross-sectional; self-selected cohort; mediation ≠ causation. ME/CFS Relevance:: Explains why ADHD/ASD + POTS co-occurrence is not coincidental: shared connective tissue biology creates an additive energy drain. Certainty Assessment::
- *Quality:* Medium (novel mediation finding)
- *Sample:* n=109
- *Replication:* Single study
- *Score:* 0.6525 Kindgren et al. 2021 — ADHD/ASD Prevalence in hEDS/HSD Children
Full Citation:: Kindgren E, Quiñones Perez A, Knez R. Prevalence of ADHD and ASD in Children with HSD or hEDS. Neuropsychiatr Dis Treat. 2021;17:379–388. (Kindgren, Quiñones Perez, and Knez 2021) DOI:: 10.2147/NDT.S290494 PMID:: 33603376 Article Type:: Retrospective study Key Findings::
- n=201 children with hEDS/HSD: ADHD 16% (+ 7% under investigation); ASD 6%
- Age 17--18 cohort: ADHD in 46%
- hEDS significantly higher ADHD than HSDConclusion:: Connective tissue hypermobility carries substantially elevated neurodevelopmental burden. The hEDS–ADHD–ASD cluster is a high-risk phenotype. Limitations:: Retrospective; single-centre; no within-study controls. ME/CFS Relevance:: Quantifies the neurodivergent–hypermobility axis; this cluster carries the highest ME/CFS predisposition risk. Certainty Assessment::
- *Quality:* Medium
- *Sample:* n=201
- *Replication:* Consistent with literature
- *Score:* 0.6026 Lau et al. 2015 — Migraine Confers 1.5× CFS Risk
Full Citation:: Lau C-I, Lin C-C, Chen W-H, et al. Increased risk of chronic fatigue syndrome in patients with migraine. J Psychosom Res. 2015;79(6):514–518. (Lau et al. 2015) DOI:: 10.1016/j.jpsychores.2015.10.005 PMID:: 26505533 Article Type:: Retrospective cohort Key Findings::
- Taiwan NHIRD: n=6,902 migraine vs. n=27,608 controls
- CFS incidence IRR ~1.5; age ≥65: IRR=2.11
- Dose-response with migraine frequencyConclusion:: Migraine history predisposes to CFS, with cumulative mitochondrial depletion as proposed mechanism. Limitations:: ICD-based diagnoses; Taiwan cohort; CFS criteria unspecified. ME/CFS Relevance:: Migraine as another metabolic reserve reducer — cumulative CSD events deplete neuronal energy stores. Certainty Assessment::
- *Quality:* Medium (large administrative cohort)
- *Sample:* n=34,510
- *Replication:* No direct replication
- *Score:* 0.6027 Wang et al. 2023 — Migraine Energy Metabolism: Mitochondrial Review
Full Citation:: Wang Y, Wang Y, Yue G, Zhao Y. Energy metabolism disturbance in migraine: From a mitochondrial point of view. Front Physiol. 2023;14:1133528. (Wang et al. 2023) DOI:: 10.3389/fphys.2023.1133528 PMID:: 37123270 Article Type:: Narrative review Key Findings::
- Migraineurs: elevated lactate, lower NAA, decreased cytochrome c oxidase
- CSD creates massive energy demand exceeding impaired recovery capacity
- Migraine and ME/CFS share identical triggers (stress, sleep deprivation, fasting, exercise)Conclusion:: Migraine is a condition of chronically reduced mitochondrial reserve. Same ETC impairments found in ME/CFS. Limitations:: Narrative review; heterogeneous sources. ME/CFS Relevance:: Provides mechanistic explanation for migraine → CFS risk (Lau 2015). Certainty Assessment::
- *Quality:* Medium
- *Sample:* Review
- *Replication:* Consistent
- *Score:* 0.6028 Colpani Filho et al. 2025 — BH4 Pathway in ASD: Systematic Review
Full Citation:: Colpani Filho C, Melfior L, Ramos SL, et al. Tetrahydrobiopterin and ASD: A Systematic Review. Brain Sciences. 2025;15(2):151. (Colpani Filho et al. 2025) DOI:: 10.3390/brainsci15020151 PMID:: 40002484 Article Type:: Systematic review Key Findings::
- Lower BH4 consistently in ASD biological samples vs. controls
- BH4 is cofactor for dopamine, serotonin, NE, and NO synthesis
- BH4 supplementation shows potential in some ASD trialsConclusion:: ASD shares the BH4 bottleneck with ME/CFS. GCH1 pathway variants may be shared genetic vulnerability. Limitations:: Variable measurement methods; heterogeneous populations; therapeutic evidence preliminary. ME/CFS Relevance:: Links ASD to BH4–ME/CFS pathway. Low BH4 → reduced NO → impaired vascular autoregulation. Certainty Assessment::
- *Quality:* Medium (systematic review)
- *Sample:* Multiple studies
- *Replication:* Consistent direction
- *Score:* 0.6029 Williams et al. 2025 — GCH1 rs841, BH4, and Neurodevelopmental Conditions
Full Citation:: Williams GE, Hausman-Cohen S, Sotos M, et al. The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health. Int J Mol Sci. 2025;26(16):8030. (Williams et al. 2025) DOI:: 10.3390/ijms26168030 PMID:: 40869351 Article Type:: Narrative review with case series Key Findings::
- GCH1 rs841 AA (~4% population): reduced BH4 → impaired dopamine/NE/serotonin/NO synthesis
- Associated with ADHD, ASD, depression, PMDD, insomnia
- n=5 case reports: BH4 supplementation improved ADHD behaviorConclusion:: GCH1 rs841 as a high-frequency shared genetic vulnerability across neurodevelopmental conditions and ME/CFS. Limitations:: Case series n=5 only; potential COI; genetic association weak. ME/CFS Relevance:: BH4 bottleneck connects ADHD, ASD, and ME/CFS through same enzymatic deficit. Certainty Assessment::
- *Quality:* Low-Medium (case series)
- *Sample:* n=5
- *Replication:* None
- *Score:* 0.4030 Berthier et al. 2025 — Cerebral Blood Flow in ADHD: Systematic Review
Full Citation:: Berthier J, Endomba FT, Lecendreux M, et al. Cerebral blood flow in ADHD: A systematic review. Neuroscience. 2025;567:67–76. (Berthier et al. 2025) DOI:: 10.1016/j.neuroscience.2024.11.075 PMID:: 39631658 Article Type:: Systematic review Key Findings::
- 20 studies (n=1,652 ADHD): resting hypoperfusion in prefrontal, temporal, basal ganglia
- Methylphenidate normalises striatal and thalamic blood flowConclusion:: ADHD shows baseline prefrontal-striatal hypoperfusion convergent with ME/CFS cerebral blood flow data. Limitations:: Heterogeneous methods; most underlying studies small. ME/CFS Relevance:: Shared vascular-metabolic vulnerability: both conditions show cerebral hypoperfusion as baseline. Certainty Assessment::
- *Quality:* Medium-High (systematic review)
- *Sample:* n=2,232 across 20 studies
- *Replication:* Consistent core finding
- *Score:* 0.6231 Almutairi et al. 2024 — Mitochondrial Dysfunction and Mitophagy in ADHD
Full Citation:: Almutairi MM, Althekair A, Almutairi F, et al. Mitochondrial dysfunction and mitophagy in ADHD. Saudi Pharm J. 2024;32(12):102212. (Almutairi et al. 2024) DOI:: 10.1016/j.jsps.2024.102212 PMC:: PMC11664080 Article Type:: Narrative review Key Findings::
- Decreased mitochondrial membrane potential and impaired oxidative phosphorylation in ADHD
- NDUFAF2 (Complex I), UCP2 variants correlated with reduced respiratory capacity
- Methylphenidate increases Parkin and reduces ROSConclusion:: Mitochondrial energy failure is a plausible ADHD mechanism parallel to ME/CFS mitochondrial dysfunction. Limitations:: Mostly preclinical; human evidence limited. ME/CFS Relevance:: Same mitochondrial impairments in both conditions support shared energy deficit model. Certainty Assessment::
- *Quality:* Low-Medium (narrative review, preclinical)
- *Sample:* Review
- *Replication:* Convergent
- *Score:* 0.3532 Chang et al. 2020 — MtDNA Haplogroups and ADHD Risk in European Americans
Full Citation:: Chang X, Liu Y, Mentch F, et al. Mitochondrial DNA haplogroups and risk of attention deficit and hyperactivity disorder in European Americans. Translational Psychiatry. 2020;10:370. (Chang et al. 2020) DOI:: 10.1038/s41398-020-01064-1 PMC:: PMC7608630 Article Type:: Case-control genetic association study Key Findings::
- n = 2,076 ADHD cases and 5,078 controls across three independent European cohorts; meta-analysis
- Haplogroups K and U: protective against ADHD (reduced risk)
- Haplogroup H\*: increased ADHD risk
- Haplogroup U also associated with less severe ME/CFS symptoms (Billing-Ross 2016) — cross-disease overlapConclusion:: mtDNA haplogroup variation influences ADHD risk in European populations. Haplogroup U emerges as a shared modifier across ADHD and ME/CFS symptom severity, suggesting a common mitochondrial energy background. Limitations:: Haplogroups inferred from SNP arrays (not whole-genome sequencing); all three cohorts from single institution; maternal inheritance confounding possible. ME/CFS Relevance:: Directly relevant to mtDNA predisposition model: haplogroup U crosses from ADHD protection to ME/CFS symptom modulation — implies shared mitochondrial substrate. Certainty Assessment::
- *Quality:* Medium-High (large n, three cohorts, meta-analysis)
- *Sample:* n = 7,154
- *Replication:* Three cohorts (same institution)
- *Score:* 0.6533 Giannoulis et al. 2024 — Systematic Review of Mitochondrial Genetic Variation in ADHD
Full Citation:: Giannoulis SV, Müller D, Kennedy JL, Gonçalves V. Systematic review of mitochondrial genetic variation in attention-deficit/hyperactivity disorder. European Child & Adolescent Psychiatry. 2024;33(6):1675–1685. (Giannoulis et al. 2024) DOI:: 10.1007/s00787-022-02030-6 PMID:: 35796884 Article Type:: Systematic review (10 primary studies from 507 screened) Key Findings::
- Increased mtDNA copy number documented in ADHD across multiple studies
- Specific SNP associations and haplogroup effects confirmed
- Both mtDNA and nuclear-encoded mitochondrial genes implicated
- Field underdeveloped relative to autism and schizophreniaConclusion:: Mitochondrial genetic variation contributes to ADHD pathophysiology. Evidence base is limited but directionally consistent. Methodology heterogeneity across primary studies limits firm conclusions. Limitations:: Only 10 studies met inclusion criteria; diverse populations and methods; most samples small; publication bias likely. ME/CFS Relevance:: Systematic evidence that ADHD carries mitochondrial genetic vulnerability — necessary foundation for shared-substrate hypothesis with ME/CFS. Certainty Assessment::
- *Quality:* Medium (systematic review of mostly small studies)
- *Sample:* n = 10 studies
- *Replication:* Consistent direction; variable effect sizes
- *Score:* 0.5834 Verma et al. 2016 — ADHD Suffers from Mitochondrial Dysfunction (Cybrid Study)
Full Citation:: Verma P, Singh A, Nthenge-Ngumbau DN, et al. Attention deficit-hyperactivity disorder suffers from mitochondrial dysfunction. BBA Clinical. 2016;6:153–158. (Verma et al. 2016) DOI:: 10.1016/j.bbacli.2016.10.003 PMC:: PMC5121149 Article Type:: Experimental study (cybrid cell lines) Key Findings::
- Cybrid cells from ADHD patient platelets (n = 3 ADHD, 4 controls, ages 5–13)
- Significantly lower cellular and mitochondrial respiration in ADHD cybrids
- Reduced ATPase6/8 transcripts; decreased Complex V activity
- Loss of mitochondrial membrane potential; elevated oxidative stress
- Mitochondrial defects transferable via patient mitochondria (cybrid proof of concept)Conclusion:: Bioenergetic crisis in patient mitochondria is a contributory factor for ADHD. The cybrid model demonstrates the dysfunction is intrinsic to mitochondria, not solely secondary to nuclear environment. Limitations:: Very small sample (n = 3); cybrid model introduces nuclear-cytoplasmic mismatch artifacts; patient age range broad; results need larger replication. ME/CFS Relevance:: Mechanistically parallel to ME/CFS muscle bioenergetics findings. ADHD and ME/CFS may share a mitochondrial floor-level energy deficit. Certainty Assessment::
- *Quality:* Low (n = 3; experimental model)
- *Sample:* n = 3 ADHD, n = 4 controls
- *Replication:* Not replicated
- *Score:* 0.3035 Öğütlü et al. 2022 — Mitochondrial Dysfunction in ADHD (Narrative Review)
Full Citation:: Öğütlü H, Kaşak M, Tabur ST. Mitochondrial Dysfunction in Attention Deficit Hyperactivity Disorder. Eurasian Journal of Medicine. 2022;54(Suppl 1):S187–S195. (Ögütlü, Kaşak, and Tabur 2022) DOI:: 10.5152/eurasianjmed.2022.22187 PMC:: PMC11163340 Article Type:: Narrative review Key Findings::
- mtDNA copy number ~1.3x higher in ADHD vs controls (multiple studies)
- Haplogroup B4 increases ADHD risk; K and U reduce risk in European populations
- 10398 A/G polymorphism significantly associated with ADHD in Korean cohort
- Mitochondrial apoptotic signaling: second strongest mechanism in ADHD cases (GWAS data)
- Both ADHD and ME/CFS share reduced spare respiratory capacity and elevated oxidative stressConclusion:: Convergent evidence positions mitochondrial dysfunction as central to ADHD, with overlapping haplogroup effects compared to ME/CFS. Haplogroup U protective in ADHD (Chang 2020) and symptom-modifying in ME/CFS (Billing-Ross 2016) — strongest cross-disease haplogroup overlap point. Limitations:: Narrative review; variable study quality in sources; blood-based biomarkers less specific than tissue; translation to brain pathophysiology uncertain. ME/CFS Relevance:: Synthesises the entire ADHD mitochondrial literature with relevance to ME/CFS predisposition model. Certainty Assessment::
- *Quality:* Medium (narrative review)
- *Sample:* Review
- *Replication:* Convergent
- *Score:* 0.4536 Fanet et al. 2021 — BH4 Pathway: From Metabolism to Neuropsychiatry
Full Citation:: Fanet H, Capuron L, Castanon N, et al. Tetrahydrobiopterin (BH4) pathway: from metabolism to neuropsychiatry. Curr Neuropharmacol. 2021;19(5):591–609. (Fanet et al. 2021) DOI:: 10.2174/1570159X18666200729103529 PMID:: 32744952 Article Type:: Narrative review Key Findings::
- BH4 cofactor for TH (dopamine/NE), TPH (serotonin), all NOS isoforms
- Inflammatory cytokines increase BH4 synthesis but accelerate oxidation → net monoamine depletion
- Reduced CSF BH4 in depression, Parkinson's, Alzheimer's, ADHD, autismConclusion:: Infection/neuroinflammation → BH4 oxidative depletion → catecholamine deficiency → ADHD-like and ME/CFS symptoms. Limitations:: Narrative review; ADHD coverage brief. ME/CFS Relevance:: Mechanistic bridge: shared inflammatory trigger → shared neurotransmitter deficit via BH4 bottleneck. Certainty Assessment::
- *Quality:* Medium
- *Sample:* Review
- *Replication:* Core biochemistry established
- *Score:* 0.5037 DelRosso et al. 2026 — Iron Deficiency in ADHD and ASD
Full Citation:: DelRosso LM, Estrada Chaverri L, Ceballos Fuentes FA. Iron Deficiency Across Neurodevelopmental Disorders. Children (Basel). 2026;13(2):180. (DelRosso, Estrada Chaverri, and Ceballos Fuentes 2026) DOI:: 10.3390/children13020180 PMID:: 41749537 Article Type:: Narrative review Key Findings::
- Reduced brain iron in dopaminergic regions in ADHD
- Iron is cofactor for dopamine synthesis AND mitochondrial complex I/II — dual role
- Ferritin thresholds: \<30 ng/mL (ADHD), \<50 ng/mL (ASD sleep phenotype)Conclusion:: Iron deficiency creates a double metabolic deficit in neurodivergent patients: impaired neurotransmitter synthesis + reduced mitochondrial capacity. A modifiable baseline reducer. Limitations:: Narrative review; peripheral iron proxies unreliable for brain iron. ME/CFS Relevance:: Iron screening and correction in neurodivergent ME/CFS patients — tractable intervention to improve metabolic reserve. Certainty Assessment::
- *Quality:* Medium
- *Sample:* Review
- *Replication:* Robust mechanistic rationale
- *Score:* 0.6038 Raw et al. 2025 — Neurodivergence as Post-COVID-19 Risk Factor
Full Citation:: Raw RK, Rees J, Pearson A, Chadwick DR. Neurodivergence as a Risk Factor for Post-COVID-19 Syndrome. COVID. 2025;6(1):1–7. (Raw et al. 2025) DOI:: 10.3390/covid6010001 Article Type:: Cross-sectional study Key Findings::
- n=267 healthcare workers: higher autistic trait scores predicted symptoms \>12 weeks
- Sensory reactivity subscale strongest predictor
- Dimensional (autistic traits, not just formal diagnosis)Conclusion:: Autistic traits predict post-COVID syndrome risk, consistent with lower-baseline model via central sensitization. Limitations:: Small sample; healthcare workers only; self-reported traits; cross-sectional. ME/CFS Relevance:: Dimensional evidence that neurodivergent biology predisposes to post-infectious fatigue. Certainty Assessment::
- *Quality:* Low-Medium
- *Sample:* n=267
- *Replication:* No
- *Score:* 0.4539 Wirth et al. 2026 — Pre-ME/CFS ICD-10 Diagnoses in Children (N=36,332)
Full Citation:: Wirth M, Haastert B, Linnenkamp U, et al. ICD-10 Diagnoses prior to ME/CFS diagnosis in children and young people suggest potential early diagnostic indicators. Sci Rep. 2026. (Wirth et al. 2026) DOI:: 10.1038/s41598-026-40848-1 PMID:: 41741569 | PMC: PMC12949141 Article Type:: Retrospective matched case-control (health insurance claims) Key Findings::
- n=6,077 pediatric ME/CFS cases matched 1:5 to 30,255 controls in German claims data 2020--2022
- 48 ICD-10 code classes significantly elevated before ME/CFS diagnosis
- Fatigue (OR 2.19), pain disorders (OR 1.55), somatoform disorders (OR 1.32), depression (OR 1.21), laryngopharyngitis (OR 1.15)
- Rare but strongly associated: post-COVID condition (OR 3.84), mild cognitive impairment (OR 2.93), fibromyalgia (OR 2.08)
- Pre-ME/CFS medical utilization window: up to 5 years before diagnosisConclusion:: Pre-ME/CFS diagnoses in children span fatigue, pain, cognitive, and autonomic symptom clusters — consistent with multi-year prodromal phase of subclinical energy deficit. Limitations:: Observational; direction of causality not established. Pre-illness psychiatric codes (depression, somatoform) may be misattributed prodromal ME/CFS symptoms. Temporal window limited to 2020–2022 (overlaps COVID pandemic). ME/CFS Relevance:: Largest evidence base (N=36,332) for pre-illness symptom clustering in children. Directly supports Architecture C predisposition framework: subclinical dysfunction visible in claims data years before formal ME/CFS threshold. Certainty Assessment::
- *Quality:* High (large N, matched design, administrative data)
- *Sample:* n=36,332
- *Replication:* Single study (2026); no independent replication yet
- *Score:* 0.7040 Collin et al. 2018 — Childhood Sleep Predicts Adolescent ME/CFS (ALSPAC)
Full Citation:: Collin SM, Norris T, Gringras P, et al. Childhood sleep and adolescent chronic fatigue syndrome (CFS/ME): evidence of associations in a UK birth cohort. Sleep Med. 2018;47:85–91. (Collin et al. 2018) DOI:: 10.1016/j.sleep.2018.01.005 PMID:: 29773208 | PMC: PMC5974860 Article Type:: Prospective birth cohort (ALSPAC) Key Findings::
- n=13,978 children followed to age 18; 242 developed chronic disabling fatigue (CDF)
- Shorter nighttime sleep, difficulty falling asleep (OR 1.74), later bedtimes, more nocturnal awakenings
- Each extra hour of sleep at age 9 cut CDF odds at age 13 by 39%; at age 11 cut CDF odds at age 16 by 51%
- Sleep abnormalities precede CDF/ME/CFS by 4--7 years — a prospective prodromal signalConclusion:: Childhood sleep disruption is a measurable precursor to adolescent ME/CFS, consistent with early autonomic dysregulation or shared pathophysiological cause. Limitations:: CDF definition may not fully align with strict ME/CFS criteria; mechanism of sleep-to-CFS pathway uncharacterized; general population sleep data, not specialist clinic. ME/CFS Relevance:: Strongest prospective prodromal evidence to date. A fatigued, sleep-disrupted child who “never feels rested” may be manifesting early autonomic dysregulation — not a behavioral problem. Supports early intervention window. Certainty Assessment::
- *Quality:* High (prospective cohort, N=13,978, 18-year follow-up)
- *Sample:* n=13,978
- *Replication:* Within ALSPAC; independent replication needed
- *Score:* 0.6541 Wyller et al. 2007 — Thermoregulatory Dysfunction in Adolescent CFS
Full Citation:: Wyller VB, Godang K, Mørkrid L, et al. Abnormal thermoregulatory responses in adolescents with chronic fatigue syndrome: relation to clinical symptoms. Pediatrics. 2007;120(1):e129–e137. (Wyller et al. 2007) DOI:: 10.1542/peds.2006-2759 PMID:: 17606539 Article Type:: Comparative clinical study Key Findings::
- n=15 adolescent CFS patients (ages 12--18) vs 57 healthy controls
- Impaired peripheral vasoconstriction during cooling; vasoconstriction events at lower temperatures
- Elevated basal NE, epinephrine, HR — central sympathetic dysregulation
- Catecholamine cooling responses comparable to controls → central rather than peripheral defect
- Increased shivering, skin color changes, cold extremities reportedConclusion:: Cold extremities in adolescent ME/CFS reflect documentable sympathetic nervous system dysfunction, not benign circulatory variation. Limitations:: Very small n=15; single center; cross-sectional (at diagnosis, not before). ME/CFS Relevance:: Validates cold hands/feet as physiological marker of sympathetic dysregulation in adolescent ME/CFS. If autonomic dysfunction precedes full diagnosis (as OI literature suggests), persistent cold extremities + fatigue in a child is a plausible early flag. Certainty Assessment::
- *Quality:* Medium (rigorous methods, very small N)
- *Sample:* n=15
- *Replication:* Sympathetic dysregulation in pediatric ME/CFS multi-study supported; specific thermoregulation protocol not widely replicated
- *Score:* 0.5042 Chu et al. 2019 — Onset Patterns and Course of ME/CFS
Full Citation:: Chu L, Valencia IJ, Garvert DW, Montoya JG. Onset Patterns and Course of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Front Pediatr. 2019;7:12. (Chu et al. 2019) DOI:: 10.3389/fped.2019.00012 Article Type:: Descriptive survey + qualitative interviews Key Findings::
- N=150 adults meeting Fukuda 1994 CFS criteria; 14 qualitative interviews
- 38% had \>6 months from initial symptom to full syndrome — multi-month prodromal window
- 79% (11/14) reported pre-illness health problems: recurrent infections, autonomic symptoms, unusual fatigue
- One participant experienced dyspnea and presyncope for months before formal onset
- Top triggers: infection 64%, stress 39%, environmental toxin 20%Conclusion:: ME/CFS onset is complex; a substantial minority have a multi-month prodromal window with autonomic and infectious precursors. Limitations:: Retrospective recall; no control group; adult sample; N=14 for qualitative phase. ME/CFS Relevance:: Supports the gradual-onset prodromal model. The 38% with >6-month prodrome represents the population where retrospective prodromal signs (exercise intolerance, sleep disruption, OI) would be detectable in childhood histories. Certainty Assessment::
- *Quality:* Medium (survey-based, no controls)
- *Sample:* n=150 (quantitative); n=14 (qualitative)
- *Replication:* Consistent with Evans & Jason 2018
- *Score:* 0.4543 Moak et al. 2024 — Small Fiber Neuropathy in Pediatric POTS/OI
Full Citation:: Moak JP, Ramwell CB, Gordish-Dressman H, Sule SD, Bettini E. Small fiber neuropathy in children, adolescents, and young adults with chronic orthostatic intolerance and POTS: A retrospective study. Auton Neurosci. 2024;253:103163. (Moak et al. 2024) DOI:: 10.1016/j.autneu.2024.103163 PMID:: 38537312 Article Type:: Retrospective cohort Key Findings::
- n=109 pediatric POTS/OI patients with neuropathic symptoms
- Skin biopsy abnormal in 53% — SFN in majority tested
- 3× probability of positive ANA or anti-thyroid antibody in SFN+ group — autoimmune substrate
- Presentation: OI + fatigue + paresthesia + brain fog + painConclusion:: Small fiber neuropathy is common in pediatric POTS/OI and may underlie the combined autonomic + neuropathic symptom constellation seen in early ME/CFS. Limitations:: Single center specialty clinic; retrospective; no healthy control biopsy group; skin biopsy only in symptomatic subgroup (selection bias). ME/CFS Relevance:: SFN causes dysautonomia, fatigue, proprioceptive deficits, and fine tremor in young patients — all plausible prodromal or early signs before ME/CFS threshold. Autoimmune substrate supports immune-mediated gradual deterioration model. Certainty Assessment::
- *Quality:* Medium (retrospective, specialty clinic, n=109)
- *Sample:* n=109
- *Replication:* SFN in POTS established in adults; pediatric-specific data emerging
- *Score:* 0.5044 Kato et al. 2006 — Premorbid Predictors of Chronic Fatigue (Twin Study)
Full Citation:: Kato K, Sullivan PF, Evengård B, Pedersen NL. Premorbid Predictors of Chronic Fatigue. Arch Gen Psychiatry. 2006;63(11):1267–1272. (Kato et al. 2006) DOI:: 10.1001/archpsyc.63.11.1267 PMID:: 17088507 Article Type:: Prospective nested case-control (Swedish Twin Registry) Key Findings::
- N=19,192 twins; pre-illness measures 25 years before fatigue onset
- Perceived life stress: 5.81× increased risk after genetic control — true environmental causal factor
- Emotional instability: elevated risk disappears in MZ discordant pairs — genetic, not environmental
- Extraversion: no associationConclusion:: Perceived stress is a true causal premorbid risk factor for chronic fatigue independent of genetics; emotional instability reflects shared genetic background. Limitations:: Outcome is broad “chronic fatigue,” not strictly ME/CFS. Psychological instruments only; no physiological biomarkers. 25-year lead time may miss onset-proximate prodromal factors. “Emotional instability” may partly reflect undetected subclinical autonomic dysregulation. ME/CFS Relevance:: Largest twin study of chronic fatigue premorbid predictors. Stress as causal factor supports physiological stress-response vulnerability model (Architecture C). Caution: emotional instability as premorbid predictor may be circular if prodromal autonomic dysfunction produces instability-like features. Certainty Assessment::
- *Quality:* High (twin design, N=19,192, 25-year prospective)
- *Sample:* n=19,192
- *Replication:* Unique design; consistent with stress-onset literature
- *Score:* 0.50 (for chronic fatigue); lower for ME/CFS specifically45 Jason et al. 2015 — CFS vs Sudden Onset ME (Null Result for Universal Prodrome)
Full Citation:: Jason LA, Evans M, Brown A, Sunnquist M, Newton JL. Chronic Fatigue Syndrome Versus Sudden Onset Myalgic Encephalomyelitis. J Prev Interv Community. 2015;43(1):6–12. (Jason et al. 2015) DOI:: 10.1080/10852352.2014.973233 PMID:: 25584529 Article Type:: Comparative observational study Key Findings::
- N=285 (DePaul n=189; Newcastle n=96)
- ME (sudden onset within 24h--1 week): more severe functional limitations, greater PEM severity
- Sudden-onset ME by definition has no prodromal gradual deterioration
- Prodromal evidence from other studies does not apply to this subgroupConclusion:: A substantial ME/CFS subpopulation has sudden onset with no prodromal phase; prodromal signs apply to gradual-onset subtype only. Limitations:: Retrospective onset categorization (recall bias); two-category classification likely oversimplified (Evans & Jason 2018). ME/CFS Relevance:: Critical null result. Claims of universal prodromal ME/CFS are incorrect. The gradual-onset subtype (with prodromal evidence from Collin 2018, Wirth 2026, Chu 2019) represents one heterogeneous presentation; sudden-onset ME patients would have different pre-illness histories. Certainty Assessment::
- *Quality:* Medium
- *Sample:* n=285
- *Replication:* Consistent with onset heterogeneity literature
- *Score:* 0.55 (null result for prodrome in sudden-onset subtype)46 Geraghty & Adeniji 2019 — Diagnostic Accuracy in Pediatric ME/CFS (Commentary)
Full Citation:: Geraghty KJ, Adeniji C. The Importance of Accurate Diagnosis of ME/CFS in Children and Adolescents: A Commentary. Front Pediatr. 2019;7:435. (Geraghty and Adeniji 2019) DOI:: 10.3389/fped.2018.00435 PMID:: 30719431 | PMC: PMC6348258 Article Type:: Commentary / narrative review Key Findings::
- 40% diagnostic error rate among children referred to specialist ME/CFS clinics
- Misdiagnosis breakdown: 47% other chronic disease, 20% primary sleep disorder, 15% psychiatric, 4% cardiovascular (likely OI/POTS)
- Adult ME/CFS: average 5-year diagnostic delay; pediatric: elevated medical utilization up to 5 years before diagnosis
- PEM most frequently missed cardinal symptom
- 80% of pediatric broad-criteria CFS cases recovered by age 18 — overdiagnosis risk with loose criteriaConclusion:: Both under- and over-diagnosis are significant problems in pediatric ME/CFS. The 5-year pre-diagnosis medical utilization window is consistent with a prodromal period, but PEM must be confirmed to avoid false positives. Limitations:: Commentary; not primary research. Error rate data from secondary sources. ME/CFS Relevance:: Documents 5-year pre-diagnosis symptom window. Sleep disorder misdiagnosis (20%) directly consistent with Collin 2018 prodromal sleep data. Cardiovascular misdiagnosis (4%) reflects OI/POTS being labeled as cardiac. Critical dual caveat: prodromal signals exist, but 80% pediatric recovery rate warns against over-pathologizing normal fatigue. Certainty Assessment::
- *Quality:* Low-Medium (commentary)
- *Sample:* Narrative synthesis
- *Replication:* Diagnostic delay data consistent across sources
- *Score:* 0.40